; or (H) a laboratory or other entity from performing safety, quality, or efficacy testing of marihuana for medical use, as authorized under such State law or under Federal law. (2) Cannabidiol Notwithstanding the exclusion of cannabidiol from the definition of marihuana in section 102 of the Controlled Substances Act ( 21 U.S.C. 802 ), as amended, and section 5 of this Act, this subsection applies with respect to cannabidiol, as defined in such section 102, to the same extent and in the same manner as this subsection applies with respect to marihuana. 3. Research into potential medicinal uses of marihuana (a) In general Not later than 180 days after the date of enactment of this Act, the Attorney General shall delegate responsibility under section 303(f) of the Controlled Substances Act ( 21 U.S.C. 823(f) ) for control over access to marihuana for research into its potential medicinal uses to an agency of the executive branch that is not focused on researching the addictive properties of substances. Such agency shall take appropriate actions to ensure that an adequate supply of marihuana is available for such medicinal research. (b) Consideration of other research in scheduling Research that is performed in a scientifically sound manner in a State where marihuana or cannabidiol is legal for medical purposes, and in accordance with such State’s law, but that does not use marihuana from federally approved sources, may be considered for purposes of rescheduling marihuana under section 202 of the Controlled Substances Act ( 21 U.S.C. 812 ). 4. Relation of act to certain prohibitions relating to smoking This Act does not affect any Federal, State, or local law regulating or prohibiting smoking in public. 5. Definitions In this Act: (1) Authorized patient The term authorized patient means an individual using marihuana in accordance with a prescription by a physician for medical use. (2) Marihuana Except as provided in section 2(c)(2), the term marihuana has the meaning given to such term in section 102 of the